INT128983

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.87
First Reported 2005
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 6
Disease Relevance 0.22
Pain Relevance 2.60

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Comt) plasma membrane (Comt) cytoplasm (Comt)
Anatomy Link Frequency
brain 1
gut 1
Comt (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Catechol-O-methyltransferase 176 100.00 Very High Very High Very High
Dopamine 75 100.00 Very High Very High Very High
Catecholamine 4 100.00 Very High Very High Very High
Morphine 7 99.00 Very High Very High Very High
Bioavailability 18 98.88 Very High Very High Very High
Opioid 4 96.80 Very High Very High Very High
mu opioid receptor 1 92.08 High High
Nucleus accumbens 2 88.68 High High
Neurotransmitter 8 84.72 Quite High
alcohol 60 50.00 Quite Low
Disease Link Frequency Relevance Heat
Disease 132 78.00 Quite High
Cognitive Disorder 46 5.00 Very Low Very Low Very Low
Dyskinesias 12 5.00 Very Low Very Low Very Low
Increased Venous Pressure Under Development 12 5.00 Very Low Very Low Very Low
Drug Dependence 10 5.00 Very Low Very Low Very Low
Attention Deficit Hyperactivity Disorder 10 5.00 Very Low Very Low Very Low
Diarrhoea 9 5.00 Very Low Very Low Very Low
Depression 7 5.00 Very Low Very Low Very Low
Hepatotoxicity 6 5.00 Very Low Very Low Very Low
Stress 6 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
An alternative pathway for the formation of
               vanillic acid is the COMT-triggered degradation of LD to 3-OMD with a subsequent
               tyrosine aminotransferase-dependent second step. 
Protein_catabolism (degradation) of COMT associated with catechol-o-methyltransferase
1) Confidence 0.87 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778405 Disease Relevance 0 Pain Relevance 0.30
Activity of the dopamine degrading enzyme catechol-O-methyltransferase (COMT) appears to increase in mid-adulthood (after age 30) based on post mortem studies (Tunbridge et al. 2007), but does not differ between infants, adolescents, and young adults.
Protein_catabolism (degrading) of COMT associated with catechol-o-methyltransferase and dopamine
2) Confidence 0.86 Published 2010 Journal Neuropsychol Rev Section Body Doc Link PMC2988999 Disease Relevance 0 Pain Relevance 0.38
A further development was the introduction of COMT inhibitors, which decrease
               peripheral LD degradation to 3-O-methyldopa (3-OMD) and thus further increase the
               delivery of LD to the brain.4,5 Two COMT-inhibitors, the only
               peripheral-acting entacapone (EN) and the additionally central-acting
                   tolcapone,6,7 are currently marketed as adjuncts
               to LD/DDI application. 
Protein_catabolism (degradation) of COMT in brain associated with catechol-o-methyltransferase
3) Confidence 0.57 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778405 Disease Relevance 0.22 Pain Relevance 0.29
Intestinal
               LD absorption is rapid and complete, but the plasma bioavailability of LD is only
               30% as a result of prior degradation to dopamine by DDI and to a lesser
               extent to 3-OMD by COMT, ie, in the gut membranes. 
Protein_catabolism (degradation) of COMT in gut associated with catechol-o-methyltransferase, dopamine and bioavailability
4) Confidence 0.57 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778405 Disease Relevance 0 Pain Relevance 0.18
Activity of the dopamine degrading enzyme catechol-O-methyltransferase (COMT) appears to increase in mid-adulthood (after age 30) based on post mortem studies (Tunbridge et al. 2007), but does not differ between infants, adolescents, and young adults.
Protein_catabolism (degrading) of enzyme catechol-O-methyltransferase associated with catechol-o-methyltransferase and dopamine
5) Confidence 0.10 Published 2010 Journal Neuropsychol Rev Section Body Doc Link PMC2988999 Disease Relevance 0 Pain Relevance 0.38
Furthermore, variability in an enzyme degrading catecholamines (COMT gene) alters the efficacy of morphine demonstrating that genetic variability in non-opioid systems may indirectly influence the clinical efficacy from morphine.
Protein_catabolism (degrading) of COMT gene associated with catecholamine, opioid and morphine
6) Confidence 0.03 Published 2005 Journal Acta Anaesthesiol Scand Section Abstract Doc Link 16045647 Disease Relevance 0 Pain Relevance 1.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox